Home Therapy With LMWH in Deep Vein Thrombosis: Randomized Study Comparing Single and Double Daily Administrations

Abstract

The aim of this study was to assess the effectiveness of low-molecular-weight heparin (LMWH) treatment of deep vein thrombosis (DVT) in terms of the evolution of thrombosis, the incidence of adverse events, and compliance with heparin treatment using 2 types of LMWH available on the market administered in therapeutic doses throughout the period of treatment (Nadroparin) or at therapeutic doses only during the first month of treatment followed by a prophylactic phase at half dose (Parnaparin). A randomized prospective study was carried out on patients under observation with a recent diagnosis of DVT. The objectives of the study were to confirm the effectiveness of therapy with LMWH in terms of prevention of the risk of thromboembolism, of relapse of DVT, and of hemorrhagic complications, and to complete an evaluation of venous recanalization and residual valve competence in the 2 groups of patients. From December 2002 to June 2005, we randomized a total of 91 patients (51 in the Parnaparin group and 40 in the Nadroparin group). Overall, there was 1 case of nonfatal pulmonary embolism (1.1%) at 7 days into therapy with LMWH. There were 3 cases (3.3%) of progression of thrombosis despite therapy with LMWH, 2 cases (5%) in the Nadroparin group, and 1 case (2%) in the Parnaparin group (P = NS), and after suspension of the therapy, there was 1 case of relapse of thrombosis. Three of the 4 thrombotic events occurred in patients with active neoplasia. Moreover, only 1 major hemorrhagic event (1.1%) required blood transfusion. The Doppler ultrasound in the follow-up showed a complete resolution of 56% of the vein thromboses at an average of 6.1 ± 4.6 (mean ± SD) months. Valve competence recovered in 65.9% of cases with no significant difference between the 2 heparin groups. Home treatment of sural and femoral-popliteal DVT using LMWH represents a safe and effective method in the prevention of pulmonary embolism and encourages the process of recanalization of the thrombosed vessel, especially in cases of sural and/or popliteal DVT. Administration can be carried out with the same degree of safety at the therapeutic dose throughout the period of treatment or can be halved after the first month of treatment. In patients with active neoplasia, treatment with oral anticoagulant therapy must be considered.

Get full access to this article

View all access options for this article.

References

Leizorovicz A. : Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the treatment of deep venous thrombosis: An updated meta-analysis . Drugs 52(suppl 7): 30-37 , 1996.

Meissner MH , Manzo RA , Bergelin RO , Strandness DE Jr : Deep venous insufficiency: The relationship between lysis and subsequent reflux . J Vasc Surg 18: 596-605 , 1993.

Fihn S. , McDonnel M. , Martin D. , et al: Risk factors for complications of chronic anticoagulation . Ann Intern Med 118: 511-520 , 1993.

Turkstra F. , Koopman MM , Buller HR : The treatment of deep vein thrombosis and pulmonary embolism . Thromb Haemost 78: 489-496 , 1997.

Gould MK , Dembitzer AD , Doyle RL : Low molecular-weight heparins and unfactionated heparin for treatment of acute deep venous thrombosis: A meta-analysis of randomized controlled trials . Ann Intern Med 130: 800-809 , 1999.

Lopez-Beret P. , Orgaz A. , Fontcuberta J. , Doblas M. : Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis . J Vasc Surg 33: 77-90 , 2001.

Prandoni P. , Lensing Awa , Büller HR , et al: Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis . Lancet 339: 441-445 , 1992

Kirchmaier CM , Lindhoff-Last E. , Rübesam D. , et al: Regression of deep vein thrombosis by i.v.: Administration of a low molecular weight heparin: Results of a pilot study . Thromb Res 73: 337-348 , 1994.

Killewich LA , Bedford GR , Beach KW , Stradness DE Jr : Spontaneous lysis of deep venous thrombi: Rate and outcome . J Vasc Surg 9: 89-97 , 1989.

10.

Hull RD , Raskob GE , Pineo GF , et al: Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis . N Engl J Med 326: 975-982 , 1992.

11.

Koopman Mmw , Prandoni P. , Piovella F. , et al: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home . N Engl J Med 334: 682-687 , 1996.

12.

Schulman S. , Rhedin AS , Lindmarker P. , et al: Duration of anticoagulation trial study group: A comparison of six weeks with six month of oral anticoagulant therapy after a first episode of venous thromboembolism . N Engl J Med 332: 1661-1665 , 1995.

13.

Van Bemmelen PS , Bedford G. , Beach K. , Stradness DE Jr : Quantitative segmental evaluation of venous valvular reflux with duplex ultrasound scanning . J Vasc Surg 10: 425-443 , 1989.

14.

Vasdekis SN , Clarke GH , Nicolaides AN : Quantification of venous reflux by means of duplex scanning . J Vasc Surg 10: 670-677 , 1989.

15.

Haenen JH , Janssen MC , van Langen H. , et al: Duplex ultrasound in the hemodynamic evaluation of the late sequelae of deep vein thrombosis . J Vasc Surg 27: 472-478 , 1998.

16.

Van Ramshorst B. , van Bemmelen P. , Hoeneveld H. , et al: Thrombus regression in deep venous thrombosis: Quantification of spontaneous thrombolysis with duplex scanning . Circulation 86: 414-419 , 1992.

17.

Buller HR , Agnelli G. , Hull RD , Hyers TM , Prins MH , Raskob GE : Antithrombotic therapy for venous thromboembolic disease . Chest 126: 401S-428S , 2004.